BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: AbdelKhalek A, Mohammad H, Mayhoub AS, Seleem MN. Screening for potent and selective anticlostridial leads among FDA-approved drugs. J Antibiot (Tokyo) 2020;73:392-409. [PMID: 32132676 DOI: 10.1038/s41429-020-0288-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Monaghan TM, Seekatz AM, Mullish BH, Moore-Gillon CCER, Dawson LF, Ahmed A, Kao D, Chan WC. Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opin Ther Targets 2021;:1-15. [PMID: 34793686 DOI: 10.1080/14728222.2021.2008907] [Reference Citation Analysis]
2 Abutaleb NS, Seleem MN. In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection. Sci Rep 2021;11:7093. [PMID: 33782498 DOI: 10.1038/s41598-021-86595-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 AbdelKhalek A, Seleem MN. Repurposing the Veterinary Antiprotozoal Drug Ronidazole for the Treatment of Clostridioides difficile Infection. Int J Antimicrob Agents 2020;56:106188. [PMID: 33045352 DOI: 10.1016/j.ijantimicag.2020.106188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pal R, Dai M, Seleem MN. High-throughput screening identifies a novel natural product-inspired scaffold capable of inhibiting Clostridioides difficile in vitro. Sci Rep 2021;11:10913. [PMID: 34035338 DOI: 10.1038/s41598-021-90314-3] [Reference Citation Analysis]
5 Phanchana M, Harnvoravongchai P, Wongkuna S, Phetruen T, Phothichaisri W, Panturat S, Pipatthana M, Charoensutthivarakul S, Chankhamhaengdecha S, Janvilisri T. Frontiers in antibiotic alternatives for Clostridioides difficile infection. World J Gastroenterol 2021; 27(42): 7210-7232 [PMID: 34876784 DOI: 10.3748/wjg.v27.i42.7210] [Reference Citation Analysis]
6 Naclerio GA, Abutaleb NS, Li D, Seleem MN, Sintim HO. Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence In Vivo. J Med Chem 2020;63:11934-44. [PMID: 32960605 DOI: 10.1021/acs.jmedchem.0c01198] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Pi H, Ogunniyi AD, Savaliya B, Nguyen HT, Page SW, Lacey E, Venter H, Trott DJ. Repurposing of the Fasciolicide Triclabendazole to Treat Infections Caused by Staphylococcus spp. and Vancomycin-Resistant Enterococci. Microorganisms 2021;9:1697. [PMID: 34442776 DOI: 10.3390/microorganisms9081697] [Reference Citation Analysis]